Table 3.

Summary of preclinical and clinical studies evaluating the therapeutic efficacy of histone acetylation modulators in pancreatic cancer.

Combination	Type of Study	NCT #	Status	Reference
HAT inhibitors
gemcitabine + C646	Preclinical			108
gemcitabine + curcumin	Clinical (Phase II)	NCT00192842	Completed, results not reported	109
HDAC Inhibitors
vorinostat + sorafenib	Preclinical			114
gemcitabine + vorinostat + sorafenib + radiation	Clinical (Phase I)	NCT02349867	Recruiting
vorinostat + capecitabine + radiation	Clinical (Phase I)	NCT00983268	Completed	115
gemcitabine + romidepsin	Clinical (Phase I)	NCT00379639	Completed	117
gemcitabine + CI-994 (Tacedinaline)	Clinical (Phase II)	NCT00004861	Completed	118
gemcitabine + MGCD0103 (Mocetinostat)	Clinical (Phase I/II)	NCT00372437	Completed, results not posted
BET Inhibitors
JQ1 + olaparib	Preclinical			127
JQ1 + vorinostat	Preclinical			128